Audioboom, Polarean and Arix Bioscience
Justin Waite
Vox Markets Podcast with Justin Waite
12:49, 21st June 2019

Vox Media Player

 

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app


On today's Vox Markets Podcast: Audioboom, Polarean and Arix Bioscience

Rob Proctor, Chief Executive Officer of Audioboom (BOOM) FOLLOW covers recent news including their podcast content funding guarantee arrangement and their collaboration with Studio71.

Audioboom is the leading global podcast company, consolidating the business of on-demand audio, making content accessible, wide-reaching and profitable for podcasters, advertisers and brands. Audioboom operates internationally, with operations and global partnerships across North America, Europe, Asia and Australia, and addresses the issue of disparate podcast services by putting all of the pieces of the puzzle together under one umbrella, creating a user-friendly, economical experience. (Interview starts at minutes seconds)


Richard Hullihen, CEO of Polarean (POLX) FOLLOW discusses the progress they are making in their Phase III Clinical Trials and milestone coming up.

Located in the Research Triangle Park area of North Carolina, Polarean Imaging plc. designs and manufactures equipment for production of hyperpolarized xenon or helium gas. When used in conjunction with MRI, these gases offer a fundamentally new and non-invasive functional imaging platform. Current investigational uses include identifying early diagnoses of respiratory diseases as well as monitoring progression and therapeutic response. In addition, xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs. Polarean Imaging plc. hyperpolarization systems are currently sold in the United States and internationally for research and investigational applications only.

(Interview starts at 22 minutes 10 seconds)


Jonathan Tobin, Investment Director Arix Bioscience (ARIX) FOLLOW provides an insight into their portfolio, investment process and strategy.

Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors

(Interview starts at 32 minutes 44 seconds)

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist